Evidence map›Paper›PMID 36430480›Full record

ArticleInternational journal of molecular sciences2022

Toward a Combination of Biomarkers for Molecular Characterization of Multiple Sclerosis.

Dafni Birmpili, Imane Charmarke Askar, Lucas Dinh Pham-Van, Thomas Kuntzel, Caroline Spenlé, Aurélien Riou, Dominique Bagnard

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dafni BirmpiliCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.ORCID 0000-0002-5331-8800
Imane Charmarke AskarCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.
Lucas Dinh Pham-VanCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.
Thomas KuntzelCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.ORCID 0000-0002-3239-5882
Caroline SpenléCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.
Aurélien RiouCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.
Dominique BagnardCNRS UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS, 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.ORCID 0000-0002-5261-902X
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system associated with chronic inflammation, demyelination, and axonal damage. MS is a highly heterogeneous disease that leads to discrepancies regarding the clinical appearance, progression, and therapy response of patients. Therefore, there is a strong unmet need for clinically relevant biomarkers capable of recapitulating the features of the disease. Experimental autoimmune encephalomyelitis (EAE) is a valuable model for studying the pathophysiology of MS as it recapitulates the main hallmarks of the disease: inflammation, blood-brain barrier (BBB) disruption, gliosis, myelin damage, and repair mechanisms. In this study, we used the EAE-PLP animal model and established a molecular RNA signature for each phase of the disease (onset, peak, remission). We compared variances of expression of known biomarkers by RT-qPCR in the brain and spinal cord of sham and EAE animals monitoring each of the five hallmarks of the disease. Using magnetic cell isolation technology, we isolated microglia and oligodendrocytes of mice of each category, and we compared the RNA expression variations. We identify genes deregulated during a restricted time frame, and we provide insight into the timing and interrelationships of pathological disease processes at the organ and cell levels.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisAnimalsBiomarkersInflammationMiceRNABiomarkersRNAbiomarkersexperimental autoimmune encephalomyelitismultiple sclerosisRNA

Identifiers

PMID36430480
PMCPMC9695566
OpenAlexW4309008608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.